These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21266724)

  • 1. Lessons from type I interferons in ulcerative colitis.
    Kaser A; Blumberg RS
    Gut; 2011 Apr; 60(4):430-1. PubMed ID: 21266724
    [No Abstract]   [Full Text] [Related]  

  • 2. Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production.
    Mannon PJ; Hornung RL; Yang Z; Yi C; Groden C; Friend J; Yao M; Strober W; Fuss IJ
    Gut; 2011 Apr; 60(4):449-55. PubMed ID: 20971977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case series: ulcerative colitis, multiple sclerosis, and interferon-beta 1a.
    Rodrigues S; Magro F; Soares J; Nunes AC; Lopes S; Marques M; Rio E; Macedo G
    Inflamm Bowel Dis; 2010 Dec; 16(12):2001-3. PubMed ID: 20186933
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.
    Schott E; Paul F; Wuerfel JT; Zipp F; Rudolph B; Wiedenmann B; Baumgart DC
    World J Gastroenterol; 2007 Jul; 13(26):3638-40. PubMed ID: 17659718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial.
    Musch E; Andus T; Malek M
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1233-9. PubMed ID: 12144572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial.
    Musch E; Andus T; Kruis W; Raedler A; Spehlmann M; Schreiber S; Krakamp B; Malek M; Malchow H; Zavada F; Engelberg Feurle G
    Clin Gastroenterol Hepatol; 2005 Jun; 3(6):581-6. PubMed ID: 15952100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I interferons for induction of remission in ulcerative colitis.
    Seow CH; Benchimol EI; Griffiths AM; Steinhart AH
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006790. PubMed ID: 18646167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I interferons for induction of remission in ulcerative colitis.
    Wang Y; MacDonald JK; Benchimol EI; Griffiths AM; Steinhart AH; Panaccione R; Seow CH
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD006790. PubMed ID: 26368001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid onset of ulcerative colitis after treatment with interferon β1a in a patient with multiple sclerosis.
    Tuna Y; Başar O; Dikici H; Köklü S
    J Crohns Colitis; 2011 Feb; 5(1):75-6. PubMed ID: 21272812
    [No Abstract]   [Full Text] [Related]  

  • 10. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study.
    Nikolaus S; Rutgeerts P; Fedorak R; Steinhart AH; Wild GE; Theuer D; Möhrle J; Schreiber S
    Gut; 2003 Sep; 52(9):1286-90. PubMed ID: 12912859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case study: interferon-beta-induced remission of ulcerative colitis in a patient with type C chronic hepatitis].
    Miike T; Tahara Y; Yamaguchi Y; Harada T; Abe H; Kusumoto K; Numata M; Hasuike S; Yamamoto S; Kodama M; Nagata K; Hayashi K; Shimoda K
    Nihon Shokakibyo Gakkai Zasshi; 2008 Sep; 105(9):1362-6. PubMed ID: 18772577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting IL-13 as a Host-Directed Therapy Against Ulcerative Colitis.
    Hoving JC
    Front Cell Infect Microbiol; 2018; 8():395. PubMed ID: 30460209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver injury associated with the beta-interferons for MS.
    Francis GS; Kaplowitz N; Alteri E
    Neurology; 2004 Sep; 63(6):1142-3; author reply 1142-3. PubMed ID: 15457586
    [No Abstract]   [Full Text] [Related]  

  • 14. Illuminating the role of type I IFNs in colitis.
    Wirtz S; Neurath MF
    J Clin Invest; 2005 Mar; 115(3):586-8. PubMed ID: 15765141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis.
    Pena-Rossi C; Schreiber S; Golubovic G; Mertz-Nielsen A; Panes J; Rachmilewitz D; Shieh MJ; Simanenkov VI; Stanton D; Graffner H
    Aliment Pharmacol Ther; 2008 Sep; 28(6):758-67. PubMed ID: 19145731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.
    Somani AK; Swick AR; Cooper KD; McCormick TS
    Arch Dermatol; 2008 Oct; 144(10):1341-9. PubMed ID: 18936398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I interferons and their therapeutic role in Th2-regulated inflammatory disorders.
    Tilg H; Kaser A
    Expert Opin Biol Ther; 2004 Apr; 4(4):469-81. PubMed ID: 15102597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of IL-13 and NK T cells in experimental and human ulcerative colitis.
    Fuss IJ; Strober W
    Mucosal Immunol; 2008 Nov; 1 Suppl 1(0 1):S31-3. PubMed ID: 19079225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment on 'Vitiligo in a COVID-19-vaccinated patient with ulcerative colitis: coincidence?': Type I interferons as possible link between COVID-19 vaccine and vitiligo.
    Abdullah L; Awada B; Kurban M; Abbas O
    Clin Exp Dermatol; 2022 Feb; 47(2):436-437. PubMed ID: 34498300
    [No Abstract]   [Full Text] [Related]  

  • 20. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells.
    Heller F; Fuss IJ; Nieuwenhuis EE; Blumberg RS; Strober W
    Immunity; 2002 Nov; 17(5):629-38. PubMed ID: 12433369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.